title: 5'UTR +24T>C CR2 is not associated with nasopharyngeal carcinoma development in the North Region of Portugal.
abstract: OBJECTIVE
  We have analysed the association of the +24T>C polymorphism (rs3813946) in CR2, the cellular receptor for Epstein-Barr virus (EBV), in the susceptibility for the development of nasopharyngeal carcinoma (NPC).
  
  
  METHODS
  A retrospective case-control study was developed with peripheral blood samples from 111 individuals with NPC and 608 healthy individuals (controls) from the North region of Portugal. The genotyping analysis was performed by allelic discrimination real-time PCR using a TaqMan(®) SNP Genotyping Assay.
  
  
  RESULTS
  The genotype distribution was 62.2% TT, 34.2% TC and 3.6% CC for NPC patients; and 65.0%, 30.6% and 4.4%, respectively, for controls. Our study showed no statistical association between the genotype distribution in controls and all types of NPC (P = 0.717); nevertheless, the analysis showed statistically significant differences (P = 0.038) regarding cases with well- or moderately differentiated types of NPC suggesting that +24CC/CT genotypes are associated with increased risk (OR = 4.16; 95% CI 1.28-15.7; P = 0.016).
  
  
  CONCLUSIONS
  This is the first study in Western populations to characterize the association of the CR2 +24T>C polymorphism in NPC development, and our results suggest that more studies are required to clarify the impact on NPC susceptibility in different populations.
authors.affiliation: Molecular Oncology and Viral Pathology Group, Portuguese Oncology Institute of Porto, Porto, Portugal.|Virology Service, Portuguese Oncology Institute of Porto, Porto, Portugal.
authors.forename: H
authors.identifier: http://orcid.org/0000-0001-5795-2131
authors.initials: H
authors.lastname: Sousa
authors.affiliation: Molecular Oncology and Viral Pathology Group, Portuguese Oncology Institute of Porto, Porto, Portugal.
authors.forename: M J
authors.initials: MJ
authors.lastname: Bastos
authors.affiliation: Molecular Oncology and Viral Pathology Group, Portuguese Oncology Institute of Porto, Porto, Portugal.
authors.forename: J
authors.initials: J
authors.lastname: Ribeiro
authors.affiliation: Molecular Oncology and Viral Pathology Group, Portuguese Oncology Institute of Porto, Porto, Portugal.
authors.forename: S
authors.initials: S
authors.lastname: Oliveira
authors.affiliation: Otorhinolaryngology Service, Portuguese Oncology Institute of Porto, Porto, Portugal.
authors.forename: E
authors.initials: E
authors.lastname: Breda
authors.affiliation: Molecular Oncology and Viral Pathology Group, Portuguese Oncology Institute of Porto, Porto, Portugal.
authors.forename: R
authors.initials: R
authors.lastname: Catarino
authors.affiliation: Molecular Oncology and Viral Pathology Group, Portuguese Oncology Institute of Porto, Porto, Portugal.|Virology Service, Portuguese Oncology Institute of Porto, Porto, Portugal.|Abel Salazar Institute for the Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.|Faculty of Health Sciences of Fernando Pessoa University, CEBIMED, Porto, Portugal.|Research Department, Portuguese League Against Cancer (Liga Portuguesa Contra o Cancro - Núcleo Regional do Norte), Porto, Portugal.
authors.forename: R
authors.initials: R
authors.lastname: Medeiros
mesh_terms: D020121:5' Untranslated Regions; D000293:Adolescent; D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000235:genetics* / Q000473:pathology*; D016022:Case-Control Studies; D002648:Child; D005260:Female; D005838:Genotype; D004854:Herpesvirus 4, Human; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000235:genetics* / Q000473:pathology*; D060787:Neoplasm Grading; D020641:Polymorphism, Single Nucleotide; D011174:Portugal; D017464:Receptors, Complement 3d / Q000235:genetics*; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D020121:5' Untranslated Regions; D017464:Receptors, Complement 3d
keywords: CR2/CD21; cancer; nasopharyngeal carcinoma; polymorphism